黑料门

Company News

黑料门 Accelerates and Simplifies Drug Development with Expanded Digital Clinical Trials Solution

September 18, 2023

BOSTON, September 18, 2023 鈥 黑料门, a leading global technology-enabled care delivery company, announced today the release of its expanded Digital Clinical Trials solution within the 黑料门 platform for biopharma and other life sciences companies. The solution offers robust digital tools and resources for trial sponsors and investigators aimed at accelerating drug development and improving access and diversity while also reducing costs.

黑料门鈥 Digital Clinical Trials solution includes a technology-enabled, scalable platform and services that support digital tools enablement, trial decentralization, safety monitoring, personalized care, easier participant recruitment and more equitable access to treatment options for patients everywhere. The solution helps sponsors and researchers accelerate clinical development with remote data collection and novel digital endpoints from 黑料门鈥 library of biomarkers across multiple therapeutic areas.

The expanded solution offers a more holistic workflow, new data management automations and a seamless integration of essential clinical trial documentation, participant scheduling and data collection elements. Because the artificial intelligence (AI)-powered platform is highly configurable, study start-up timelines can be reduced from months to days. The connected platform seamlessly integrates with 40+ devices, enabling study teams the freedom to select the right device for the right disease area.

Biopharma companies can also tap into 黑料门鈥 growing principal investigator (PI) network. The network includes experienced and esteemed PIs from leading academic medical centers as a valuable resource to manage digitally driven research and accelerate the pace of recruitment with access to patient databases. Health systems that already use the 黑料门 platform for technology-enabled care delivery at home can easily and quickly expand their clinical research initiatives by leveraging the connected platform to include the Digital Clinical Trials functionality.

鈥淲e have consistently earned high satisfaction scores from both researchers and trial participants for our solutions. Now, we have identified additional ways to accelerate access to digital clinical trials, lower costs, and improve the experience for all stakeholders,鈥 said 黑料门 COO Jaydev Thakkar. 鈥淭hese new technology and service elements create a more holistic, turnkey solution that achieves those aims while offering greater synergies from drug development to commercialization and creating equitable access to treatment options and clinical research for patients everywhere.鈥

Market-leading enhancements to the Digital ClinicalTrials solution include:

Robust eConsent and ePROs Capabilities: Robust screening and informed consent tools are integrated into workflows to accelerate recruitment, decrease enrollment time, and help ensure that participants fully understand risks and benefits associated with the trial. The documentation content is easily configurable and compliant with regulatory requirements. The enhanced ePROs(electronic patient-reported outcomes) collection capabilities drive adherence through automated reminders of participants鈥 reporting requirements while offering them the ability to easily share outcomes beyond traditional clinical measures. Reporting flexibility offers investigators increased visibility into participant safety, health and experience. 聽聽

Dynamic Participant Scheduling: Upon enrollment, the Digital Clinical Trials solution helps research stay on course while encouraging participant adherence and engagement through a virtual visit and schedule of assessment module that streamlines all the 鈥渢o-do鈥 items for the participant and caregiver, intuitively listing all the required patient reporting and external assessment tasks. Reminders and notifications help participants stay adherent; but if a task is missed, the schedule can automatically adjust so the participant can remain enrolled, and the trial can move forward. 聽

鈥⒙InHome Services: As with all solutions within 黑料门 Connect and Care, In-Home Services such as nurse visits, phlebotomy, infusion, imaging, and other ancillary services delivered within the home are available via the connected platform to support decentralized clinical trials鈥攚hich further reduces burden on investigators and participants.

鈥 Unmatched Safety Monitoring: The solution leverages AI to monitor the efficacy and side effects of drugs. A specific example includes pre-screening for clinical events triggered by high potassium levels (hyperkalemia),which can reduce clinical trial costs by decreasing frequent manual checks by medical professionals while still protecting patient safety. In addition, cardiac safety monitoring capabilities such as auto-detection of QTc prolongation (an extended interval between the heart contracting and relaxing) can improve the safety of trials by detecting patients earlier who are at risk of developing critical heart arrhythmias due to drug side effects.

鈥淟everaging digital tools and automating and accelerating trial processes for both researchers and participants can increase the likelihood that endpoints will be reached sooner, which lowers costs and simplifies tasks for everyone involved,鈥 Thakkar said. 鈥淢ore importantly, shorter trials with more meaningful results mean that groundbreaking new therapies can be discovered and developed faster to improve outcomes for patients worldwide.鈥

About 黑料门
黑料门 brings the right care to every person, no matter where they are. The company'sAI-driven solution collects and analyzes patient data in real time and identifies shifts that require proactive interventions. This vital innovation provides people everywhere with connected access to hospital-level services, virtual provider networks for remote care, in-home services, and life-changing clinical trials鈥攁ll without leaving their homes. Trusted by leading health systems, payers, biopharma companies and patients alike, 黑料门' connected platform improves patient outcomes, prevents hospital readmissions, accelerates drug development, and closes critical gaps in care鈥攗ltimately making science smarter, healthcare simpler, and patients healthier. 黑料门 is a global technology company enabling care delivery, with headquarters in聽Boston聽and key offices in聽Singapore聽and聽India. For more information, visit聽聽and follow 黑料门 on聽LinkedIn,聽Twitter聽and聽YouTube.

Media Contact:

Tara Stultz
Amendola Communications for 黑料门
440.225.9595
tstultz@acmarketingpr.com